GSK: Nucala treatment approved in China

(CercleFinance.com) - GSK announces that Nucala (mepolizumab) has been approved in China for the treatment of adults with chronic rhinosinusitis with nasal polyps.


This monoclonal antibody targets interleukin-5 (IL-5), as adjunctive therapy with intranasal corticosteroids for the treatment of adult patients with NPSw for whom systemic corticosteroid therapy and/or surgery do not provide adequate disease control.

GSK is delighted that Nucala has been approved in China as a treatment for NPSc, a chronic disease for which effective new therapies are needed. Patients now have a non-surgical option and an alternative to repeated exposure to oral corticosteroids.

It is estimated that around 107 million people in China suffer from chronic sinusitis, of whom around 1/3 have chronic sinusitis with nasal polyps. People with TNSCw experience symptoms such as nasal obstruction, loss of smell, facial pressure, sleep disturbance and nasal discharge, which can significantly affect their emotional and physical well-being.


Copyright (c) 2025 CercleFinance.com. All rights reserved.